AlessiaGottliebMD

Psychiatry • Los Angeles, CA

Child & Adolescent Psychiatry

Physician

Join to view full profile

Are you Dr. Gottlieb?

Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.

Connect with colleagues in the same hospital or clinic
You already have 62 invites waiting!
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

Claim this profile

Not you? Find your profile

Office
300 Medical Plz
Los Angeles, CA 90095
Phone+1 310-825-9989

Fax+1 310-301-8751
Is this information wrong?

Summary

Dr. Alessia Gottlieb, MD is a board certified psychiatrist in Los Angeles, California. She is currently licensed to practice medicine in California and New York.

Education & Training

UCLA David Geffen School of Medicine/UCLA Medical CenterFellowship, Child and Adolescent Psychiatry, 2001 - 2003
UCLA David Geffen School of Medicine/UCLA Medical CenterResidency, Psychiatry, 1997 - 2001
Cedars-Sinai Medical CenterInternship, Transitional Year, 1993 - 1994
Columbia University Vagelos College of Physicians and SurgeonsClass of 1993

Certifications & Licensure

NY State Medical License 2010 - 2025
CA State Medical License 1996 - 2025
American Board of Psychiatry and Neurology Child & Adolescent Psychiatry

Publications & Presentations

PubMed

A prospective phase III, randomized, double-blind, placebo-controlled study of brodalumab in patients with moderate-to-severe plaque psoriasis.
Papp KA, Reich K, Paul C, Blauvelt A, Baran W, Bolduc C, Toth D, Langley RG, Cather J, Gottlieb AB, Thaçi D, Krueger JG, Russell CB, Milmont CE, Li J, Klekotka PA, Kri...> ;Br. J. Dermatol.. 2016-08-01
Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate-to-severe plaque psoriasis over 52 weeks: a phase III, randomized c...
Paul C, Cather J, Gooderham M, Poulin Y, Mrowietz U, Ferrandiz C, Crowley J, Hu C, Stevens RM, Shah K, Day RM, Girolomoni G, Gottlieb AB> ;Br. J. Dermatol.. 2015-12-01
Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: results from two randomized, placebo-controlled, phase III trials.
Papp KA, Menter MA, Abe M, Elewski B, Feldman SR, Gottlieb AB, Langley R, Luger T, Thaci D, Buonanno M, Gupta P, Proulx J, Lan S, Wolk R> ;Br. J. Dermatol.. 2015-10-01
Downmodulation of key inflammatory cell markers with a topical Janus kinase 1/2 inhibitor.
Punwani N, Burn T, Scherle P, Flores R, Shi J, Collier P, Hertel D, Haley P, Lo Y, Waeltz P, Rodgers J, Shepard S, Vaddi K, Yeleswaram S, Levy R, Williams W, Gottlieb AB> ;Br. J. Dermatol.. 2015-10-01
Tildrakizumab (MK-3222), an anti-interleukin-23p19 monoclonal antibody, improves psoriasis in a phase IIb randomized placebo-controlled trial.
Papp K, Thaçi D, Reich K, Riedl E, Langley RG, Krueger JG, Gottlieb AB, Nakagawa H, Bowman EP, Mehta A, Li Q, Zhou Y, Shames R> ;Br. J. Dermatol.. 2015-10-01
Tumour necrosis factor-α inhibition can stabilize disease in progressive vitiligo.
Webb KC, Tung R, Winterfield LS, Gottlieb AB, Eby JM, Henning SW, Le Poole IC> ;Br. J. Dermatol.. 2015-09-01
Secukinumab administration by pre-filled syringe: efficacy, safety and usability results from a randomized controlled trial in psoriasis (FEATURE).
Blauvelt A, Prinz JC, Gottlieb AB, Kingo K, Sofen H, Ruer-Mulard M, Singh V, Pathan R, Papavassilis C, Cooper S> ;Br. J. Dermatol.. 2015-02-01
Secukinumab improves hand, foot and nail lesions in moderate-to-severe plaque psoriasis: subanalysis of a randomized, double-blind, placebo-controlled, regimen-finding...
Paul C, Reich K, Gottlieb AB, Mrowietz U, Philipp S, Nakayama J, Harfst E, Guettner A, Papavassilis C> ;J Eur Acad Dermatol Venereol. 2014-12-01
Diagnosing and treating psoriatic arthritis: an update.
Boehncke WH, Qureshi A, Merola JF, Thaçi D, Krueger GG, Walsh J, Kim N, Gottlieb AB> ;Br. J. Dermatol.. 2014-04-01
Safety results from a pooled analysis of randomized, controlled phase II and III clinical trials and interim data from an open-label extension trial of the interleukin...
Langley RG, Papp K, Gottlieb AB, Krueger GG, Gordon KB, Williams D, Valdes J, Setze C, Strober B> ;J Eur Acad Dermatol Venereol. 2013-10-01
A randomized, double-blind, placebo-controlled study to evaluate the addition of methotrexate to etanercept in patients with moderate to severe plaque psoriasis.
Gottlieb, A. B.,Langley, R. G.,Strober, B. E.,Papp, K. A.,Klekotka, P.,Creamer, K.,Thompson, E. H.,Hooper, M.,Kricorian, G.> ;Br. J. Dermatol.. 2012 Sep
Successful treatment of moderate to severe plaque psoriasis with the PEGylated Fab' certolizumab pegol: results of a phase II randomized, placebo-controlled trial with...
Reich K, Ortonne J, Gottlieb AB, Terpstra IJ, Coteur G, Tasset C, Mease P> ;Br. J. Dermatol.. 2012-07-01
Efficacy and safety of briakinumab vs. etanercept and placebo in patients with moderate to severe chronic plaque psoriasis.
Gottlieb AB, Leonardi C, Kerdel F, Mehlis S, Olds M, Williams DA> ;Br. J. Dermatol.. 2011-09-01
Infliximab improves health-related quality of life in the presence of comorbidities among patients with moderate-to-severe psoriasis.
Feldman SR, Gottlieb AB, Bala M, Wu Y, Eisenberg D, Guzzo C, Li S, Dooley LT, Menter A> ;Br. J. Dermatol.. 2008-09-01
Efalizumab: results of a 3-year continuous dosing study for the long-term control of psoriasis.
Leonardi C, Menter A, Hamilton T, Caro I, Xing B, Gottlieb AB> ;Br. J. Dermatol.. 2008-05-01
Effects of etanercept therapy on fatigue and symptoms of depression in subjects treated for moderate to severe plaque psoriasis for up to 96 weeks.
Krishnan R, Cella D, Leonardi C, Papp K, Gottlieb AB, Dunn M, Chiou CF, Patel V, Jahreis A> ;Br. J. Dermatol.. 2007-12-01
Comparison of clinical and pharmacokinetic profiles of etanercept 25 mg twice weekly and 50 mg once weekly in patients with psoriasis.
Elewski B, Leonardi C, Gottlieb AB, Strober BE, Simiens MA, Dunn M, Jahreis A> ;Br. J. Dermatol.. 2007-01-01
Oral pimecrolimus in the treatment of moderate to severe chronic plaque-type psoriasis: a double-blind, multicentre, randomized, dose-finding trial.
Gottlieb AB, Griffiths CEM, Ho VC, Lahfa M, Mrowietz U, Murrell DF, Ortonne J, Todd G, Cherill R, Marks I, Emady-Azar S, Paul CF> ;Br. J. Dermatol.. 2005-06-01
Infliximab treatment results in significant improvement in the quality of life of patients with severe psoriasis: a double-blind placebo-controlled trial.
Feldman SR, Gordon KB, Bala M, Evans R, Li S, Dooley LT, Guzzo C, Patel K, Menter A, Gottlieb AB> ;Br. J. Dermatol.. 2005-05-01
Two considerations for patients with psoriasis and their clinicians: what defines mild, moderate, and severe psoriasis? What constitutes a clinically significant impro...
Krueger GG, Feldman SR, Camisa C, Duvic M, Elder JT, Gottlieb AB, Koo J, Krueger JG, Lebwohl M, Lowe N, Menter A, Morison WL, Prystowsky JH, Shupack JL, Taylor JR, Wei...> ;J. Am. Acad. Dermatol.. 2000-08-01
Join now to see all